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Abstract
Background: Cardiac iron overload is the leading cause of death in thalassemia major and is
usually assessed using myocardial T2* measurements. Recently a cardiovascular magnetic
resonance (CMR) breath-hold T2 sequence has been developed as a possible alternative. This
cardiac T2 technique has good interstudy reproducibility, but its transferability to different centres
has not yet been investigated.
Methods and Results: The breath-hold black blood spin echo T2 sequence was installed and
validated on 1.5T Siemens MR scanners at 4 different centres across the world. Using this
sequence, 5–10 thalassemia patients from each centre were scanned twice locally within a week
for local interstudy reproducibility (n = 34) and all were rescanned within one month at the
standardization centre in London (intersite reproducibility). The local interstudy reproducibility
(coefficient of variance) and mean difference were 4.4% and -0.06 ms. The intersite reproducibility
and mean difference between scanners were 5.2% and -0.07 ms.
Conclusion: The breath-hold myocardial T2 technique is transferable between Siemens scanners
with good intersite and local interstudy reproducibility. This technique may have value in the
diagnosis and management of patients with iron overload conditions such as thalassemia.
Introduction
The development of transfusion related iron overload in
the tissue of myocardium can result in cardiomyopathy
[1,2], and heart failure remains the leading cause of death
Published: 21 February 2008
Journal of Cardiovascular Magnetic Resonance 2008, 10:11 doi:10.1186/1532-429X-10-11
Received: 7 February 2008
Accepted: 21 February 2008
This article is available from: http://www.jcmr-online.com/content/10/1/11
© 2008 He et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Cardiovascular Magnetic Resonance 2008, 10:11 http://www.jcmr-online.com/content/10/1/11
Page 2 of 4
(page number not for citation purposes)
in beta-thalassemia major (TM) [3,4]. Myocardial iron
measurement is important for assessing the risk of cardiac
complications [5,6], because of the frequency of myocar-
dial siderosis in thalassemia major [2], and the benefit of
tailoring appropriate iron-chelating treatment [7-10].
Cardiovascular magnetic resonance (CMR) provides a
non-invasive means of measuring the amount of tissue
iron. With CMR, the iron deposition results in shortening
of proton relaxation times and both T2 and T2* measure-
ments have been exploited to assess iron overload [7,11].
Myocardial T2* is fast and simple to implement and has
demonstrated good reproducibility in assessing tissue
iron content [12-14]. A similar T2 sequence, however, is
technically more difficult, and early attempts at imple-
mentation were unsatisfactory for myocardial iron meas-
urements due to problems associated with hardware
constraints, flow, cardiac motion, and noise [15,16].
However, T2 is known to vary with myocardial iron
[17,18], and there may be potential advantages of T2 over
T2* for the avoidance of problems caused by factors such
as shimming and local susceptibility. There is also interest
in comparing the myocardial T2* with T2 to discover if
additional useful clinical information can be gleaned as to
the chemical state of the stored iron. For this purpose, a
breath-hold T2 technique has been developed and
recently reported [19]. This T2 technique has demon-
strated good interstudy reproducibility in London. How-
ever, in order to be applicable in healthcare on a wider
scale, its transferability between scanners of different cent-
ers must be established, but no data on this challenging
issue is available to date. We now describe the results of
the transfer of this technique to different scanners at 4 dif-
ferent centers in different countries.
Methods
MR protocols and study population
The standard center in London used a 1.5T Siemens
Sonata scanner. Four other international centers using
1.5T MR scanners were involved in this study. Scanner
details were as follows: Center 1, Siemens Sonata (Hong
Kong, China); Center 2, Siemens Avanto (Philadelphia,
USA); Center 3 Siemens Avanto (Singapore); Center 4,
Siemens Symphony Quantum (Izmir, Turkey). The
breath-hold black blood T2 sequence developed at Lon-
don center was installed on each local scanner. The pulse
sequence details and methods of T2 calculation have been
previously described [19]. In brief, all centers used a four-
element cardiac phased array coil to image a single 10 mm
mid-ventricular short axis slice at 12 echoes times (rang-
ing from 4.8 ms to 163.2 ms, increment 14.4 ms) with
ECG gating. Double inversion recovery pulses were
applied to suppress the blood signal and data was
acquired every other cardiac cycle. For T2 measurement, a
region of interest (ROI) was chosen in the left ventricular
septum individually. The mean signal intensity of ROI
was measured for each of the images, and the data were
plotted against the TEs to form a decay curve. The mono-
exponential decay model and the nonlinear curve fitting
algorithm were used to fit the curve to obtain T2 measure-
ment. The sequence parameters were kept identical in all
centers although small variations would not be expected
to affect the T2 measurement.
A total of 34 (mean age 32 ± 9 years) TM patients (10 from
Hong Kong, 10 from Singapore, 9 from Philadelphia, 5
from Izmir) were studied. For local interstudy reproduci-
bility, these patients were scanned twice at their local cent-
ers within one week. All patients were subsequently
rescanned at the standardization center at London (inter-
site reproducibility) within four weeks of their original
scans. These patients had been regularly transfused since
early childhood or since the introduction of deferoxam-
ine, and were receiving regular iron chelation. Ethical
approval was granted at the standard center and all local
centers involved. All patients gave written informed con-
sent.
Statistics
To quantify both interstudy reproducibility and intersite
transferability, the coefficient of variation was calculated
(CoV), defined as standard deviation of the differences
between the two separate measurements, divided by their
mean and expressed as a percentage. Mean differences in
T2 between scans are also quoted as a measure of bias.
Summary data were expressed with 95% confidence inter-
vals and displayed graphically using scatter plots with line
of identity and Bland-Altman plots. Group data were
compared using Friedman's test. A p value of < 0.05 was
considered statistically significant.
Results
Myocardial T2 measurements (two at each local site and
one in London) were 46.4 ± 26.3 ms, 46.4 ± 26.1 ms and
46.3 ± 26.4 ms respectively. Friedman's test showed no
significant difference (p = 0.87, n = 34) between these
three T2 measurements.
Local interstudy reproducibility
The mean difference was -0.06 ms and the CoV for local
interstudy reproducibility was found to be 4.4%. These
values are consistent with those of our previous published
data [19]. There was no bias between the two measure-
ments (Figure 1).
Intersite reproducibility
The mean difference was -0.07 ms and the CoV for inter-
site reproducibility was found to be 5.2%. These values
were similar to those of local interstudy reproducibility
mentioned above. This demonstrates good agreementJournal of Cardiovascular Magnetic Resonance 2008, 10:11 http://www.jcmr-online.com/content/10/1/11
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between the standard center scanner and the local scan-
ners at each center and no bias was found (Figure 2).
Discussion
This study shows that the myocardial T2 values using the
recently developed breath-hold T2 sequence agree very
well between 1.5 Tesla scanners in different locations
around the world. This demonstration of transferability
suggests that this technique could be further disseminated
worldwide, should its clinical applicability be demon-
strated in iron overload conditions. Although the iron
deposition affects both T2 and T2* relaxation times, T2 is
not affected by extrinsic magnetic field inhomogeneity.
Therefore, T2 in principle might provide more accurate
measurements. Nevertheless, T2* has substantial clinical
validation both in heart and liver suggesting that the
potential limitations are more theoretical than real.[19]
One potential advantage of T2 might be to perform robust
multi-segmental analysis to explore the regional iron dis-
tribution, because T2* is currently limited to the septum
to avoid susceptibility effects from the anterior and poste-
rior cardiac veins and lungs. This may in due course
improve our understanding of how other factors affect
T2* across the myocardium. It is possible that different
chemical forms of iron in the tissue could have differential
effects between T2 and T2*, and measurement of both
parameters might be useful if chelators access different
forms of iron at different rates. From our studies of both
T2* and T2, it is likely that both parameters can assess the
tissue iron accurately in the heart using state-of-the-art
sequences, and combined analysis may provide more
information for patient management. Further research is
needed to determine this. One limitation of this study was
that only Siemens scanners were involved, and results
from other scanners would be useful. There is no substan-
tial barrier to this once the sequence has been adapted by
other manufacturers.
To conclude, this study has demonstrated the good inter-
site reproducibility of the breath-hold T2 technique
between 1.5T Siemens MR scanners at different centers
across different countries. With widespread application,
this T2 technique might yield new insights into the assess-
ment of myocardial iron and may have clinical applica-
tion possibly in conjunction with T2*.
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Assessment of interstudy reproducibility at the centers (n =  34) Figure 1
Assessment of interstudy reproducibility at the cent-
ers (n = 34). A) Bland-Altman plot of the myocardial T2 val-
ues obtained locally twice within a week, with the 95% 
confidence intervals shown as a dotted line. B) Scatter plot of 
the myocardial T2 values obtained locally twice within a 
week. The diagonal line shows the line of identity.
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Assessment of intersite reproducibility between local centers  and the standard center in London (n = 34) Figure 2
Assessment of intersite reproducibility between local 
centers and the standard center in London (n = 34). 
A) Bland-Altman plot of the myocardial T2 values obtained 
locally and at London within a month, with the 95% confi-
dence intervals shown as a dotted line. B) Scatter plot of the 
myocardial T2 values obtained locally and at London within a 
month. The diagonal line shows the line of identity.
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